How a Pharmaceutical Company Reduced Its Business Downtime

  • by Oliver Kapaun, Expert Support Consultant, SAP
  • Mara Meyer, Service Architect, SAP
  • June 16, 2011
Restrictions to system availability are costly and present long-term risks for companies. Software maintenance and modernization impose outages. Follow a brief case study of a company in the pharmaceutical business and learn its strategies for staying within its maximum tolerable business downtime using much cheaper conventional methods than near zero downtime (NZDT).

A pharmaceutical company that our team worked with (XYZ Pharma) underwent a release upgrade and Unicode conversion program of five complex system landscapes that included different releases in different regions. In addition, the company implemented SAP Advanced Planning & Optimization (SAP APO) 7.0. During the course of this project, XYZ Pharma required a solution to go through the upgrade while minimizing the downtime, so as not to lose valuable business.

We’ll walk you through our recommendations, including how we helped them through a twin upgrade and Unicode conversion (TU&UC). We’ll also show how we solved performance issues. Let’s start by looking at the difference between near-zero downtime (NZDT) and conventional methods.

Oliver Kapaun

Oliver Kapaun graduated in economics and computer science at the University of Technology Darmstadt and has worked at SAP AG since 2002. Oliver is developing on-site services for MaxAttention customers. His areas of expertise include Java and ABAP technology, applications such as ESS, MSS, and MDM, and several other focus areas in the context of SAP technology.

See more by this author

Mara Meyer

Mara Meyer studied economics and computer science at the University of Technology Darmstadt and later graduated from University Hagen. She has worked at SAP since 2001. Mara worked in SAP consulting, specializing in upgrades and database migrations, and is currently supporting MaxAttention customers globally.

See more by this author


Comments

No comments have been submitted on this article. 


Please log in to post a comment.

To learn more about subscription access to premium content, click here.